Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Tiny Machines Working to Elucidate Mechanisms of Cerebrovascular Pathologies

Project description

Tiny machines to improve cerebrovascular pathologies treatment

Tiny machines (TMs) offer precise drug delivery, enhancing bioavailability while protecting healthy cells. However, their application in the complex brain environment requires innovative designs. Supported by the Marie Skłodowska-Curie Actions programme, the CMT-DN project aims to advance drug delivery systems by training researchers to PhD level. These future experts will focus on engineering TMs and developing brain-on-chip devices to improve treatments for cerebrovascular diseases. The project will then test the engineered TMs in 3D microphysiological non-animal technologies with integrated vascularised brain organoids (both healthy and diseased). These approaches promise to reduce the cost and time of pre-clinical animal studies while accelerating therapeutic development.

Objective

The CerebroMachinesTrain Doctoral Network (CMT-DN) seeks to go beyond the state-of-the-art of drug delivery systems by focusing on tiny machines (TMs) that can be engineered as stable formulation devices capable of: i) transporting the desired amount of therapeutic substance (drug) to a target area; ii) preserving its designed function under variable physiological parameters; iii) enhancing drug bioavailability; iv) preserving the healthy environment (cells, tissues, organs) with minimal to no side effects. These TMs will require innovative engineering designs to face the complex brain environment in which they must perform as a first organ testing platform.
CMT-DN aims to train and transform a young, talented generation of 14 researchers to PhD level and as future leaders in the state-of-the-art engineering of TMs and brain-on-chip devices (VRAINORG) for unravelling the mechanisms and improved treatment options underlying cerebrovascular pathologies. The engineered TMs will be designed to work and tested against VRAINORG platforms, which are 3D non-animal technologies of vascularised brain organoids (healthy and disease models) incorporated within microphysiological systems (MPs). This innovative training programme will bring together a panel of academic and industry experts in TMs biomimetic therapeutic systems and brain MPs comprising five academic and four industry partner beneficiaries, consolidated through three academic and two industry-associated partners covering nine countries across Europe and beyond, including one US associated partner. By employing these emerging non-animal technologies (i.e. vascularised brain-on-chip models), the resulting innovative therapeutic systems will benefit from facilitated clinical translation while reducing the high cost and time-consuming aspects of pre-clinical animal studies.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA Doctoral Networks

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2024-DN-01

See all projects funded under this call

Coordinator

UNIVERSITY OF GALWAY
Net EU contribution
€ 1 364 348,16
Address
UNIVERSITY ROAD
H91 Galway
Ireland
Region
Ireland Northern and Western West
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Participants (8)

Partners (5)